Literature DB >> 14717669

Ki67 expression in bronchial preneoplastic lesions and carcinoma in situ defined according to the new 1999 WHO/IASLC criteria: a preliminary study.

A-P Meert1, F Feoli, B Martin, J-M Verdebout, C Mascaux, A Verhest, V Ninane, J-P Sculier.   

Abstract

AIMS: The World Health Organization classification of bronchial intraepithelial neoplastic lesions has been shown to be reproducible. However little is known about its biological value. The aim of this study was to assess the proliferative activity of mild (MiD), moderate (MoD), severe (SD) dysplasia and carcinoma in situ (CIS) by the expression of Ki67 on biopsy specimens obtained during fluorescence bronchoscopy. METHODS AND
RESULTS: The percentage of Ki67+ lesional nuclei was calculated in each lesion. In addition, the presence of Ki67 clusters (defined as a group of at least two strongly Ki67+ nuclei located in the upper third of the epithelium) and a Ki67 score were evaluated. The Ki67 score depended on the proportion of the stained nuclei and on the intensity of staining. MiD, MoD, SD and CIS showed increased Ki67 staining (respectively, 10%, 20%, 30% and 40% median values of positive cells). Thirty-one percent MiD, 77% MoD, 91% SD and 100% CIS showed one or more positive clusters. When only multiple clusters were considered the difference between high- and low-grade lesions was accentuated. Ki67+ clusters were more frequent in SD (91%) and CIS (94%) compared with MiD (15%) and MoD (22%). This difference was statistically significant (P < 0.01). Evaluation of the Ki67 score was in line with the above results: high grade lesions (SD and CIS) more often showed scores >4 (P = 0.05 between MiD plus MoD versus SD plus CIS).
CONCLUSIONS: Ki67 expression increases from MiD to CIS with a statistically significant difference between MiD plus MoD and SD plus CIS. These results suggest that, in terms of Ki67 positivity, SD behaves like CIS rather than like MiD or MoD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14717669     DOI: 10.1111/j.1365-2559.2004.01748.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  5 in total

1.  EGFR/erB-1, HER2/erB-2, CK7, LP34, Ki67 and P53 expression in preneoplastic lesions of bronchial epithelium: an immunohistochemical and genetic study.

Authors:  Vítor Sousa; Joana Espírito Santo; Maria Silva; Teresa Cabral; Ana Maria Alarcão; Ana Gomes; Patrícia Couceiro; Lina Carvalho
Journal:  Virchows Arch       Date:  2011-03-22       Impact factor: 4.064

2.  Inclusion of biomarkers for detecting perturbations in the heart and lung and lipid/carbohydrate metabolism in National Toxicology Program studies.

Authors:  June K Dunnick; Kristina A Thayer; Gregory S Travlos
Journal:  Toxicol Sci       Date:  2007-05-08       Impact factor: 4.849

3.  Proliferative changes in the bronchial epithelium of former smokers treated with retinoids.

Authors:  Walter N Hittelman; Diane D Liu; Jonathan M Kurie; Reuben Lotan; Jin Soo Lee; Fadlo Khuri; Heladio Ibarguen; Rodolfo C Morice; Garrett Walsh; Jack A Roth; John Minna; Jae Y Ro; Anita Broxson; Waun Ki Hong; J Jack Lee
Journal:  J Natl Cancer Inst       Date:  2007-10-30       Impact factor: 13.506

Review 4.  Assessing efficacy in early-phase cancer prevention clinical trials: the case of ki-67 in the lung.

Authors:  Eva Szabo
Journal:  Cancer Prev Res (Phila)       Date:  2010-01-26

5.  Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study.

Authors:  B Ghanim; T Klikovits; M A Hoda; G Lang; I Szirtes; U Setinek; A Rozsas; F Renyi-Vamos; V Laszlo; M Grusch; M Filipits; A Scheed; M Jakopovic; M Samarzija; L Brcic; D Stancic-Rokotov; I Kern; A Rozman; G Dekan; W Klepetko; W Berger; T Glasz; B Dome; B Hegedus
Journal:  Br J Cancer       Date:  2015-01-29       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.